



ALMA MATER STUDIORUM  
UNIVERSITÀ DI BOLOGNA

DIPARTIMENTO  
DI FARMACIA  
E BIOTECNOLOGIE

## AVVISO DI SEMINARIO

Il giorno **2 Luglio 2024**  
alle ore **11:30**

### **Dott.ssa Monica Binaschi**

Preclinical and Translational Sciences, Global Head - Menarini Research, Rome, Italy

(ospite di Prof. Giovanni Capranico)

terrà un seminario in lingua italiana dal titolo:

## **From the Discovery to the Approval of Elacestrant: the first oral SERD in Breast Cancer**

Area tematica:  
Drug discovery and development

*in presenza:*  
**Aula 2, via Belmeloro 6, Bologna BO**

Collegli e studenti sono cordialmente invitati

## **ABSTRACT**

Breast cancer is the most frequent malignancy among women and is a heterogeneous disease characterized by various histopathological and molecular features, that results in different clinical outcomes and responses to interventions. The HR+/Her2- is the most common subtype of breast cancer and endocrine therapy is the mainstay of treatment for this subtype with the objective of reducing hormone levels to inhibit estrogen receptor. Some patients however develop endocrine therapy resistance involving the development of mutations in ESR1 gene.

Elacestrant, a selective estrogen receptor degrader (SERD), has been the first oral SERD to show positive results in a pivotal Phase III trial as monotherapy versus standard of care (EMERALD study) for the treatment of ER+/HER2- advanced or metastatic breast cancer. Based on these results ORSERDU was approved by FDA last year for ESR1-mutated advanced or metastatic breast cancers with disease progression following at least one line of endocrine therapy.

During the talk, Elacestrant journey, from the discovery up to the approval, will be discussed.

## **BIOGRAPHICAL SKETCHES**

Currently, She is Preclinical and Translational Sciences, Global Head | Menarini Research | Rome, Italy

### Education

PhD in Experimental Medicine –Sapienza University, Rome, IT

Qualification as a Professional Biologist – University of Milan, IT

Degree in Biological Sciences (Hons) - University of Milan, IT

Final grade: 110/110 (summa cum laude)

52 scientific papers and selected abstracts at major conferences

Winner of GALENO PRIZE (Italy)- Young Researcher 2003.